Audion Therapeutics, Eli Lilly deal

Hearing loss company Audion received exclusive rights to undisclosed compounds from Eli Lilly in development to treat hearing loss via hair cell regeneration. Under the deal, Lilly has an option to reacquire the compounds after clinical proof of concept (POC). The companies declined to disclose details, including the stage of development of the compounds, what is considered POC and financial terms. ...